Clay Beauregard

Biography

Dr Clay Beauregard, Director, Center for Therapeutic Development, Baylor Institute for Immunology Research (BIIR). Clay has over 10 years’ experience in pharmaceutical R&D and project team management for biologics and small molecules for numerous indications. He currently leads preclinical development efforts for DC-targeting antibodies, fusions and conjugates at BIIR. Prior to joining BIIR in 2012, he was a principal scientist at Alcon, a Novartis company. Clay completed postdoctoral fellowships in immunology at Harvard Medical School and University of Texas Southwestern Medical Center after receiving his PhD in pharmacology from Texas A&M University College of Medicine. Dr Clay Beauregard, Director, Center for Therapeutic Development, Baylor Institute for Immunology Research (BIIR). Clay has over 10 years’ experience in pharmaceutical R&D and project team management for biologics and small molecules for numerous indications. He currently leads preclinical development efforts for DC-targeting antibodies, fusions and conjugates at BIIR. Prior to joining BIIR in 2012, he was a principal scientist at Alcon, a Novartis company. Clay completed postdoctoral fellowships in immunology at Harvard Medical School and University of Texas Southwestern Medical Center after receiving his PhD in pharmacology from Texas A&M University College of Medicine.

Research Interest

Pharmaceutical Sciences